A Phase 2 interventional study of GS-9674 and Placebo to match GS-9674 in Nonalcoholic Steatohepatitis (NASH), sponsored by Gilead Sciences. Completed at 37 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-29.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 9th largest by enrollment, is one of 6 that started in 2016, is one of 11 in phase 2, and was the 8th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).
Key Inclusion Criteria:
Meets the following conditions:
Key Exclusion Criteria:
Cirrhosis of the liver
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
Drug: GS-9674 · Drug: Placebo to match GS-9674
GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
Drug: GS-9674 · Drug: Placebo to match GS-9674
Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
Drug: Placebo to match GS-9674
Tablet administered orally once daily
Tablet(s) administered orally once daily
Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
TEAEs were defined as 1 or both of the following: 1) Any adverse events (AE) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug, 2) Any AEs leading to premature discontinuation of study drug.
Time frame: Up to 24 weeks plus 30 days
Overall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study.
Time frame: Up to 24 weeks plus 30 days
Participants were enrolled at study sites in North America, Hong Kong, New Zealand, and Europe. The first participant was screened on 26 October 2016. The last study visit occurred on 09 January 2018.
| Milestone | GS-9674 100 mg | GS-9674 30 mg | Placebo |
|---|---|---|---|
| Started | 56 | 56 | 28 |
| Completed | 53 | 49 | 24 |
| Not completed | 3 | 7 | 4 |
| Withdrew: Adverse event | 1 | 5 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
| Withdrew: Withdrew consent | 1 | 0 | 1 |
| Withdrew: Investigator's discretion | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
TEAEs were defined as 1 or both of the following: 1) Any adverse events (AE) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug, 2) Any AEs leading to premature discontinuation of study drug.
| Percentage of participants | GS-9674 100 mg | GS-9674 30 mg | Placebo |
|---|---|---|---|
| TEAEs | 89.3 | 76.8 | 67.9 |
| TEAEs leading to premature discontinuation of drug | 1.8 | 8.9 | 7.1 |
Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study.
| Percentage of participants | GS-9674 100 mg | GS-9674 30 mg | Placebo |
|---|---|---|---|
| Any Grade ≥ 1 | 89.3 | 92.9 | 92.9 |
| Grade 1 | 35.7 | 42.9 | 50.0 |
| Grade 2 | 37.5 | 37.5 | 25.0 |
| Grade 3 | 7.1 | 10.7 | 14.3 |
| Grade 4 | 8.9 | 1.8 | 3.6 |
Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GS-9674 100 mg | 0/56 (0%) | 2/56 (3.6%) | 39/56 (69.6%) |
| GS-9674 30 mg | 0/56 (0%) | 2/56 (3.6%) | 34/56 (60.7%) |
| Placebo | 0/28 (0%) | 1/28 (3.6%) | 17/28 (60.7%) |
| Event | GS-9674 100 mg | GS-9674 30 mg | Placebo |
|---|---|---|---|
| Hypertensive crisisVascular disorders | 0/56 | 0/56 | 1/28 |
| Bile duct stoneHepatobiliary disorders | 1/56 | 0/56 | 0/28 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/56 | 0/56 | 0/28 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 1/56 | 0/28 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 1/56 | 0/28 |
| Pelvic painReproductive system and breast disorders | 0/56 | 1/56 | 0/28 |
| Event | GS-9674 100 mg | GS-9674 30 mg | Placebo |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 13/56 | 9/56 | 5/28 |
| HeadacheNervous system disorders | 4/56 | 6/56 | 4/28 |
| FatigueGeneral disorders | 2/56 | 7/56 | 1/28 |
| Abdominal distensionGastrointestinal disorders | 2/56 | 3/56 | 3/28 |
| NasopharyngitisInfections and infestations | 1/56 | 3/56 | 3/28 |
| Upper respiratory tract infectionInfections and infestations | 6/56 | 5/56 | 2/28 |
| Back painMusculoskeletal and connective tissue disorders | 2/56 | 4/56 | 3/28 |
| Abdominal painGastrointestinal disorders | 5/56 | 2/56 | 0/28 |
| Abdominal pain upperGastrointestinal disorders | 3/56 | 5/56 | 1/28 |
| DepressionPsychiatric disorders | 1/56 | 5/56 | 0/28 |
Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(Years) | GS-9674 100 mg | GS-9674 30 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 55 ± 10.5 | 51 ± 12.8 | 50 ± 9.9 | 53 ± 11.5 |
| Sex: Female, Male(Participants) | GS-9674 100 mg | GS-9674 30 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 35 | 37 | 15 | 87 |
| Male | 21 | 19 | 13 | 53 |
| Ethnicity (NIH/OMB)(Participants) | GS-9674 100 mg | GS-9674 30 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 17 | 19 | 8 | 44 |
| Not Hispanic or Latino | 39 | 37 | 20 | 96 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | GS-9674 100 mg | GS-9674 30 mg | Placebo | Total |
|---|---|---|---|---|
| Race, Customized — American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Race, Customized — Asian | 13 | 5 | 4 | 22 |
| Race, Customized — Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 |
| Race, Customized — Black or African American | 1 | 1 | 1 | 3 |
| Race, Customized — White | 42 | 47 | 21 | 110 |
| Race, Customized — Other | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | GS-9674 100 mg | GS-9674 30 mg | Placebo | Total |
|---|---|---|---|---|
| New Zealand | 1 | 2 | 1 | 4 |
| Canada | 12 | 7 | 6 | 25 |
| Hong Kong | 5 | 2 | 3 | 10 |
| United States | 37 | 43 | 16 | 96 |
| United Kingdom | 1 | 0 | 0 | 1 |
| Switzerland | 0 | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Jan 2018, 14 months.
Results were first posted in Jan 2019, 1 year after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 14 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor
Non-alcoholic Fatty Liver Disease →